Generic drugmaker Aurobindo Pharma’s consolidated net profit declined 10% to ₹845.5 crore for the quarter ended December from ₹939.9 crore a year earlier amid lower formulations revenue in the key U.S. market.
The net profit came on a 8.5% increase in the revenue from operations to ₹7,978.5 crore (₹7,351.7 crore). Total expenditure increased to ₹6,937.5 crore (₹6,249.2 crore).
Formulations revenue increased by 10.8% to ₹6,973 crore (₹6,291 crore). U.S. formulations revenue declined 2.3% to ₹3,671 crore mainly drive by lower transient product sales. In dollar terms, the decline was 3.7% to $435 million. The formulations revenues from Europe and Growth markets were higher.
Revenue from active pharmaceutical ingredients (API) declined 1.6% to ₹1,006 crore (₹1,022 crore), while ARV formulations segment revenue increased 71.2% to ₹307 crore (₹179 crore), the company said.
It was the highest-ever quarterly revenue, driven by volume growth from diverse and expanding product portfolio coupled with new launches. “This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements…” Vice-Chairman and Managing Director K.Nithyananda Reddy said.
Published – February 06, 2025 10:31 pm IST
